Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday. The change is effective January 1.
Then, Novo Nordisk said Tuesday that it will slash the list prices of several of its popular pre-filled insulin pens and vials by up to 75%. However, the company did not announce an expansion of its programs that cut patients' out-of-pocket costs, which has been a focus of President Joe Biden and congressional Democrats. It runs several programs to lower costs for people with diabetes.
Last year, congressional Democrats passed the Inflation Reduction Act, which reduces Medicare beneficiaries' out-of-pocket cost for insulin to $35 per month per prescription starting this year. Republicans blocked a measure to extend that price cap to those covered by private insurance. Demand for insulin has grown significantly as diabetes has become the fastest-growing chronic disease in the world, a 2022 study found.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ABC7NY - 🏆 592. / 51 Read more »